Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Chugai to Join High-Quality Protein Crystal Growth Experiment in Kibo Space Lab
March 24, 2014
- OrphanPacific Voluntarily Recalls Buphenyl Tablets
March 24, 2014
- Hospira Voluntarily Recalls 9 Generic Anticancer Agents Due to Incomplete Labeling
March 24, 2014
- Maruho Files NDA for Acne Drug in Japan
March 20, 2014
- Astellas Seeks US Approval for Additional Indication of Enzalutamide
March 20, 2014
- Astellas, Daiichi Sankyo Hook Up in Compound Library Sharing
March 20, 2014
- Galderma Files NDA for Cancer Odor Treatment
March 20, 2014
- Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
- Sanofi Settles Allegra Generic Suit with Elmed Eisai, Kobayashi Kako
March 19, 2014
- Daiichi Sankyo Files NDA for Methylene Blue for Methemoglobinemia
March 19, 2014
- Genzyme Asia Pacific Senior VP to Run Japan Operations
March 18, 2014
- Novartis Workers were Acting for Office of SIGN Trial Initiator Group: University of Tokyo
March 17, 2014
- Bayer Yakuhin Chairman Eiki to Step Down
March 17, 2014
- LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
- Nichi-Iko to Name Company Succeeded from Astellas “Nichi-Iko Pharma Tech”
March 14, 2014
- Takeda to Abolish CCO Post, Commercial Operations to Come Directly Under Weber’s Control
March 14, 2014
- Will Original Drug Makers Suddenly Embrace AGs? Comments of MHLW Official Could Spark Big Changes
March 14, 2014
- Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
- Santen to Create New Exec Posts to Accelerate Globalization
March 13, 2014
- Novartis Japan Sales Tick Up 0.8%, Diovan Down 13%, Tasigna Up 35%
March 13, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…